GSK plc
GSK
$37.56
$0.411.10%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -13.09% | -29.53% | -46.81% | -57.52% | -72.22% |
| Total Depreciation and Amortization | 47.97% | 32.62% | 15.38% | 95.62% | 33.86% |
| Total Amortization of Deferred Charges | 7.16% | 7.16% | 7.16% | 5.24% | 5.24% |
| Total Other Non-Cash Items | 785,582.16% | 344.37% | 203.35% | -122.26% | 100.00% |
| Change in Net Operating Assets | -159.95% | -174.30% | 137.46% | 169.89% | 126.85% |
| Cash from Operations | 6.80% | -10.29% | -0.79% | 39.38% | 70.93% |
| Capital Expenditure | -1.18% | -4.15% | -9.37% | -9.67% | -12.47% |
| Sale of Property, Plant, and Equipment | 230.74% | 200.96% | 138.58% | -92.44% | -85.05% |
| Cash Acquisitions | -6.20% | 58.53% | 43.12% | 50.10% | 80.83% |
| Divestitures | -105.22% | -131.34% | -137.24% | -159.93% | -165.56% |
| Other Investing Activities | -159.13% | -101.46% | -15.45% | 853.91% | 805.89% |
| Cash from Investing | -1,043.99% | -69.43% | 19.54% | 105.55% | 106.90% |
| Total Debt Issued | 300.74% | 1,138.91% | 501.35% | -149.18% | -147.15% |
| Total Debt Repaid | -23.56% | 13.76% | 2.04% | 2.67% | 37.67% |
| Issuance of Common Stock | -25.00% | -36.36% | 66.67% | 90.91% | 5.26% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -8.80% | -11.71% | -11.75% | -6.56% | 0.10% |
| Other Financing Activities | -7.66% | -11.83% | -8.72% | 18.46% | -311.76% |
| Cash from Financing | 52.37% | 54.87% | 14.29% | -126.95% | -188.37% |
| Foreign Exchange rate Adjustments | -77.31% | 45.44% | 43.11% | -366.91% | -69.62% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 352.82% | 1,343.70% | 202.46% | 104.40% | 96.15% |